<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01127659</url>
  </required_header>
  <id_info>
    <org_study_id>NIH testosterone grant</org_study_id>
    <secondary_id>R01DK075877</secondary_id>
    <nct_id>NCT01127659</nct_id>
  </id_info>
  <brief_title>Testosterone Replacement in Men With Diabetes and Obesity</brief_title>
  <official_title>Effect of Hypogonadotrophic Hypogonadism and Treatment With Testosterone on Insulin Sensitivity, Inflammation, Body Composition and Sexual Function in Obese and Type 2 Diabetic Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of having testosterone deficiency in men
      with diabetes and with obesity. The study will also evaluate the effect of testosterone
      therapy. This will be done by comparing the changes in several body response indicators
      following treatment with testosterone in diabetic or obese-non diabetic men with low
      testosterone levels and comparing them to diabetic or obese-non diabetic men with low
      testosterone who are not treated with testosterone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypogonadotropic hypogonadism (HH) occurs in approximately one-third of obese and type 2
      diabetic men. Considering that there are 24 million diabetic and 100 million obese people, of
      which half are males, obesity and type 2 diabetes potentially constitute the major cause of
      hypogonadism in the population. We hypothesize that 1) HH in obese and type 2 diabetic men is
      associated with decreased insulin sensitivity, increased fat tissue mass, decreased lean body
      mass, increased inflammatory and oxidative stress, impaired sexual function and depressed
      mood as compared to diabetic and obese men with normal testosterone concentrations; and that
      2) testosterone replacement for 24 weeks in men with HH leads to an improvement in these
      parameters. Our proposed study would be the first prospective, randomized trial to
      comprehensively evaluate the effect of HH on insulin sensitivity, body composition,
      inflammatory and oxidative indices in obese and type 2 diabetic subjects and the effect of
      six months of T replacement on these parameters. The study will have 2 arms (obese and type 2
      diabetic arm) with 120 subjects in Diabetes arm and 80 subjects in obese arm. Half of men in
      each arm will have HH and half men will have normal testosterone concentrations(eugonadal
      men). Insulin sensitivity will be assessed by hyperinsulinemic-euglycemic clamps.
      Subcutaneous fat mass and lean body mass will be measured by DEXA and intra-abdominal
      (visceral) fat mass by MRI. All subjects will undergo hyperinsulinemic-euglycemic clamp, MRI,
      DEXA and give blood and urine samples (for measurement of inflammatory and oxidative stress)
      at baseline. Men with HH will then be randomized to receive testosterone or placebo gel for a
      total of 24 weeks. These men will undergo hyperinsulinemic-euglycemic clamps and give blood
      and urine samples for inflammation and oxidative stress at 4 weeks and 24 weeks. MRI and DEXA
      examinations will be carried out at 24 weeks again in men with HH. The primary endpoint of
      the study is to define a difference in whole body glucose uptake during
      hyperinsulinemic-euglycemic clamps between hypogonadal and eugonadal diabetes patients at
      baseline and an increase in glucose uptake in HH subjects after treatment with testosterone
      for 24 weeks. 30 subjects per group(testosterone and placebo gel each) will provide adequate
      power (0.8) to detect a significant difference of 10% in whole body glucose uptake. Therefore
      there will be 60 men with HH in each arm in diabetes group. For baseline comparisons, 60 men
      with normal testosterone concentrations will also be needed in each arm. We will recruit 40
      obese patients in each arm. Thus there will be 120 diabetic men and 80 obese men in the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>measured by HE clamps (baseline and 6 mths)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Composition</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>diabetes with HH-active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetes with normal testosterone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Eugonadal subjects with diabetes. They will not be treated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obese with HH-active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>obese with normal testosterone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Eugonadal non-diabetic obese subjects. They will not be treated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes with HH-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese with HH-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone</intervention_name>
    <description>intramuscular every 2 weeks</description>
    <arm_group_label>diabetes with HH-active</arm_group_label>
    <arm_group_label>obese with HH-active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline intramuscular every 2 weeks</description>
    <arm_group_label>Diabetes with HH-placebo</arm_group_label>
    <arm_group_label>Obese with HH-placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2D arm: Males with age 30-65 years

          -  Obese non-diabetic arm: Obese non-diabetic males with age 30-65 years

        Exclusion Criteria:

        1)Coronary event or procedure(myocardial infarction, unstable angina, coronary artery
        bypass, surgery or coronary angioplasty) in the previous twelve weeks; 2) PSA &gt; 4ng/ml;
        3)Hemoglobin A1c &gt; 8%; 4)h/o prostate carcinoma; 5)Hepatic disease (transaminase &gt; 3 times
        normal) or cirrhosis; 6)Renal impairment (defined as GFR&lt;30); 7)HIV or Hepatitis C positive
        status; 9)Participation in any other concurrent clinical trial; 10)Any other
        life-threatening, non-cardiac disease; 11)Use of over the counter health supplements which
        contain androgens; 12)Use of an investigational agent or therapeutic regimen within 30 days
        of study; 13)prostate nodule or severe enlargement on digital rectal examination; 14)Use of
        testosterone currently or in the past 4 months; 15)Hematocrit &gt; 50%; 16)History of
        untreated severe obstructive sleep apnea(defined as apnea-hypopnea index â‰¥30); 17)symptoms
        suggestive of severe BPH; 18)Congestive heart failure, class III or IV; 20)Known to have
        anemia secondary to iron, B12 or folic acid deficiency; 21)bone marrow disorder such as
        myelodysplasia or aplastic anemia; 22) currently suffering from symptomatic depression,
        with or without treatment; 23) history of severe depression in the past which needed
        hospitalization; 24)currently suffering from foot ulcer, significant periodontal disease or
        any other chronic infectious condition; 25)planning to have children. 26) Subjects on
        testosterone or with testosterone replacement in the past 4 months will be excluded.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>115 Flint Road</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <results_first_submitted>January 13, 2017</results_first_submitted>
  <results_first_submitted_qc>January 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2017</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Paresh Dandona</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>hypogonadism</keyword>
  <keyword>obesity</keyword>
  <keyword>testosterone</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diabetes With HH: Testosterone</title>
          <description>active drug diabetes arm
testosterone: intramuscular every 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Diabetes With HH: Placebo</title>
          <description>placebo diabetes arm
placebo: saline intramuscular every 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>Obese Testosterone</title>
          <description>active drug obese arm
testosterone: intramuscular every 2 weeks</description>
        </group>
        <group group_id="P4">
          <title>Obese Placebo</title>
          <description>placebo obese arm
placebo: saline intramuscular every 2 weeks</description>
        </group>
        <group group_id="P5">
          <title>Eugonadal Diabetes</title>
          <description>no intervention</description>
        </group>
        <group group_id="P6">
          <title>Eugonadal Obese</title>
          <description>no intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diabetes With HH: Testosterone</title>
          <description>active drug diabetes hypogonadal arm
testosterone: intramuscular every 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Obese With HH: Testosterone</title>
          <description>active drug obese hypogonadal arm
testosterone: intramuscular every 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Obese With HH: Placebo</title>
          <description>placebo obese hypogonadal arm
placebo: saline intramuscular every 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>Diabetes With HH: Placebo</title>
          <description>placebo diabetes hypogonadal arm
placebo: saline intramuscular every 2 weeks</description>
        </group>
        <group group_id="B5">
          <title>Eugonadal Diabetes</title>
          <description>diabetic men with normal testosterone</description>
        </group>
        <group group_id="B6">
          <title>Eugonadal Obese</title>
          <description>obese non-diabetic men with normal testosterone</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="50"/>
            <count group_id="B6" value="21"/>
            <count group_id="B7" value="137"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="7"/>
                    <measurement group_id="B2" value="46" spread="9"/>
                    <measurement group_id="B3" value="53" spread="7"/>
                    <measurement group_id="B4" value="54" spread="9"/>
                    <measurement group_id="B5" value="52" spread="9"/>
                    <measurement group_id="B6" value="50" spread="8"/>
                    <measurement group_id="B7" value="52" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity</title>
        <description>measured by HE clamps (baseline and 6 mths)</description>
        <time_frame>6 months</time_frame>
        <population>Glucose infusion rate in HE clamps was measured</population>
        <group_list>
          <group group_id="O1">
            <title>Diabetes With HH: Testosterone</title>
            <description>active drug diabetes hypogonadal arm
testosterone: intramuscular every 2 weeks
Glucose infusion rate: 6.5+/-4.0 mg/kg fat-free mass/min</description>
          </group>
          <group group_id="O2">
            <title>Diabetes With HH: Placebo</title>
            <description>placebo diabetes hypogonadal arm
placebo: saline intramuscular every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Obese With HH: Testosterone</title>
            <description>active drug obese hypogonadal arm
testosterone: intramuscular every 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>Obese With HH: Placebo</title>
            <description>placebo obese hypogonadal arm
placebo: saline intramuscular every 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Eugonadal Diabetes</title>
            <description>diabetic men with normal testosterone
Glucose infusion rate: 10.29+/-5.55 mg/kg fat-free mass/min</description>
          </group>
          <group group_id="O6">
            <title>Eugonadal Obese</title>
            <description>obese non-diabetic men with normal testosterone</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>measured by HE clamps (baseline and 6 mths)</description>
          <population>Glucose infusion rate in HE clamps was measured</population>
          <units>mg/kg fat free mass/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.66" spread="4.36"/>
                    <measurement group_id="O2" value="5.12" spread="2.79"/>
                    <measurement group_id="O3" value="11.37" spread="8.83"/>
                    <measurement group_id="O4" value="12.93" spread="5.16"/>
                    <measurement group_id="O5" value="10.29" spread="5.55"/>
                    <measurement group_id="O6" value="12.30" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.73" spread="4.27"/>
                    <measurement group_id="O2" value="5.06" spread="3.62"/>
                    <measurement group_id="O3" value="12.96" spread="7.11"/>
                    <measurement group_id="O4" value="14.57" spread="1.71"/>
                    <measurement group_id="O5" value="NA">These subjects did not undergo intervention</measurement>
                    <measurement group_id="O6" value="NA">These subjects did not undergo intervention</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation</title>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diabetes With HH: Testosterone</title>
          <description>active drug diabetes hypogonadal arm
testosterone: intramuscular every 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Diabetes With HH: Placebo</title>
          <description>placebo diabetes hypogonadal arm
placebo: saline intramuscular every 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>Obese With HH: Testosterone</title>
          <description>active drug obese hypogonadal arm
testosterone: intramuscular every 2 weeks</description>
        </group>
        <group group_id="E4">
          <title>Obese With HH: Placebo</title>
          <description>placebo obese hypogonadal arm
placebo: saline intramuscular every 2 weeks</description>
        </group>
        <group group_id="E5">
          <title>Eugonadal Diabetes</title>
          <description>diabetic men with normal testosterone</description>
        </group>
        <group group_id="E6">
          <title>Eugonadal Obese</title>
          <description>obese non-diabetic men with normal testosterone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paresh Dandona</name_or_title>
      <organization>University of Buffalo</organization>
      <phone>716) 961-9900</phone>
      <email>pdandona@kaleidahealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

